- Home
- ALXO vs FLC Comparison
ALXO vs FLC Comparison
Compare ALXO & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALXO | FLC |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.8M | 162.4M |
| IPO Year | 2020 | 2003 |
Fundamental Metrics
Financial Performance| Metric | ALXO | FLC |
|---|---|---|
| Price | $1.18 | $15.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $4.60 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 42.6K |
| Earning Date | 11-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.86 | $15.33 |
| 52 Week High | $2.66 | $18.09 |
Technical Indicators
Market Signals| Indicator | ALXO | FLC |
|---|---|---|
| Relative Strength Index (RSI) | 42.79 | 37.20 |
| Support Level | $0.86 | $15.33 |
| Resistance Level | $1.29 | $15.85 |
| Average True Range (ATR) | 0.14 | 0.20 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 69.20 | 13.46 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.